drugset
Drugs / EPHARNA
last change Mar 2017 re-read 3 minutes ago

EPHARNA

also known as EphA2 siRNA

Small interfering RNA (siRNA) targets EPHA2 via inhibition

Developed for
cancer
Investigated by
Gateway for Cancer Research · Institutional Funding for Federally Supported Clinical Trials (IFSCT) · M.D. Anderson Cancer Center · National Cancer Institute (NCI)

Trials 1

today NCT01591356 · Ph 1
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01591356 Jul 2015 → Apr 2027 expected cancer M.D. Anderson Cancer Center Active not recruiting No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as EPHARNA “EphA2-targeted therapeutic (EPHARNA).” PMID 28265009 ↗ Mar 2017
Known as EphA2 siRNA “This phase I trial studies the side effects and best dose of EphA2 siRNA in treating patients with solid tumors” NCT01591356 ↗
Action Inhibit “EphA2-targeting DOPC-encapsulated siRNA may slow the growth of tumor cells by shutting down the activity of a gene that causes tumor growth.” NCT01591356 ↗
Modality Small interfering RNA (siRNA) “EphA2-targeting DOPC-encapsulated siRNA” NCT01591356 ↗
Route Intravenous “administered intravenously” NCT01591356 ↗
Target EPHA2 “EphA2-targeting DOPC-encapsulated siRNA” NCT01591356 ↗